Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer.

• Smith, M.B. ^[1] ; Reardon, J. ^[1]
  1. [1] Ohio State University

     Ohio State University

     City of Columbus, Estados Unidos

     
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 48, Nº. 11, 2012, págs. 713-722
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Pertuzumab is a humanized monoclonal antibody directed at the dimerization domain of the receptor tyrosine-protein kinase erbB-2 (HER2) receptor. It possesses a unique and complimentary mechanism of action compared to trastuzumab, which has historically been the cornerstone of therapy for HER2-amplified breast cancer. Clinical trials demonstrate improved outcomes, with minimal increases in toxicity with the addition of pertuzumab to trastuzumab in patients with HER2-positive metastatic breast cancer, indicating the advantage of dual HER2 receptor blockade. Pertuzumab is approved as first-line therapy in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer, with future opportunities to investigate its efficacy in other stages of breast cancer, as well as in the treatment of other malignancies.